<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7450</journal-id>
<journal-title><![CDATA[Revista Colombiana de Psiquiatría]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.psiquiatr.]]></abbrev-journal-title>
<issn>0034-7450</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Psiquiatria.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74502024000400419</article-id>
<article-id pub-id-type="doi">10.1016/j.rcp.2022.05.003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diferencias atencionales entre el trastorno por déficit de atención aislado y asociado a neurofibromatosis tipo 1]]></article-title>
<article-title xml:lang="en"><![CDATA[Attentional Differences Between Isolated Attention Deficit Disorder and Attention Deficit Disorder Associated with Neurofibromatosis Type 1]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vaucheret Paz]]></surname>
<given-names><![CDATA[Esteban]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortolá]]></surname>
<given-names><![CDATA[Rosario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cestari]]></surname>
<given-names><![CDATA[Matias]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordoba]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leist]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Petracca]]></surname>
<given-names><![CDATA[Luciana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chirilla]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Appendino]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Italiano de Buenos Aires  ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>53</volume>
<numero>4</numero>
<fpage>419</fpage>
<lpage>425</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74502024000400419&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74502024000400419&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74502024000400419&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La incidencia de TDAH en pacientes con NF1 llega al 60%. Más allá de la bibliografía publicada sobre aspectos cognitivos en sujetos con NF1, algunos estudios indican que el perfil atencional de los pacientes con NF1+TDAH es distinto de los sujetos con TDAH solo. Métodos: Estudio retrospectivo, analítico de casos y controles con el objetivo de comparar el perfil intelectual y atencional en niños con NF1+TDAH, NF1 y TDAH solo para caracterizarlos constatando similitudes y diferencias.  Resultados:  Se revisaron evaluaciones neuropsicológicas de 2017 a 2021 de todos los sujetos con diagnóstico de NF1 (n = 46) con CIT &gt; 70 y TDAH (n = 180). En la prueba ANOVA se observó que los pacientes con NF1+TDAH presentaron mayor deterioro visuoespacial (M = 84,66; F(2)210)=7,84; p &lt; 0,001; &#951;2=0,07) y menor nivel intelectual total (M = 84,20; F(2)223) =4,35; p = 0,01; &#951;2 = 0,04); en las pruebas atencionales mostraron más errores por omisión (M = 72,66; F(2)223) = 18,13; p &lt; 0,001; &#951;2 = 0,14) y por comisión (M = 57,87; F(2,223) = 4,68; p = 0,01; &#951;2 = 0,04) y menor velocidad de reacción (M = 66,58; F(2223) = 19,24; p &lt; 0,001; &#951;2 = 0,15) en comparación con los pacientes con NF1 y TDAH aislado.  Conclusiones:  El déficit atencional en los pacientes con NF1 se asocia a un menor rendimiento en el funcionamiento intelectual y mayor compromiso visoespacial. El patrón atencional de los pacientes con NF1+TDAH fue diferente de los sujetos con TDAH solo; la diferencia fue no solo cuantitativa, sino también cualitativa, lo que sustenta la hipótesis de que el deterioro de la atención tiene rasgos propios de la NF1 e independientes del TDAH.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The incidence of ADHD in patients with NF1 reaches 60%. Beyond the published literature on cognitive aspects in subjects with NF1, some studies suggest that the attentional profile of patients with NF1+ADHD is different from those with isolated ADHD. Methods: A retrospective, analytical case-control study with the objective of comparing the intellectual and attentional profile in children with NF1+ADHD, NF1 and isolated ADHD in order to characterise them, noting similarities and differences.  Results:  Neuropsychological evaluations from 2017 to 2021 were reviewed for all subjects with a diagnosis of NF1 (n = 46) with IQ&gt;70 and ADHD (n= 180). In the ANOVA test, it was observed that patients with NF1+ADHD presented with greater visuospatial impairment (M = 84.66; F(2,210) = 7.84; P&lt; 0,001; &#951;2 = 0.07) and a lower total intellectual level (M = 84.20; F(2,223) =4,35; P = 0.01; &#951;2 =0.04). In the attentional tests they showed more errors of omission (M = 72.66; F(2,223) = 18.13; P&lt; .001; &#951;2 = 0.14) and of commission (M = 57,87; F(2,223) = 4.68; P = 0,01; &#951;2 = 0.04) and lower reaction speed (M = 66.58; F(2,223) = 19.24; P&lt; 0.001; &#951;2 = 0.15) compared to patients with NF1 and isolated ADHD.  Conclusions:  Attention deficit in patients with NF1 is associated with lower performance in intellectual functioning and greater visuospatial impairment. The attentional pattern of patients with NF1+ADHD was different from those with isolated ADHD; the difference being not only quantitative but also qualitative, supporting the hypothesis that attention impairment has its own features of NF1 and independent of ADHD.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Neurofibromatosis]]></kwd>
<kwd lng="es"><![CDATA[Trastorno por déficit de atención con hiperactividad]]></kwd>
<kwd lng="es"><![CDATA[Test neuropsicológicos]]></kwd>
<kwd lng="es"><![CDATA[Síndrome neurocutáneo]]></kwd>
<kwd lng="es"><![CDATA[Pediatría]]></kwd>
<kwd lng="en"><![CDATA[Neurofibromatosis]]></kwd>
<kwd lng="en"><![CDATA[Attention deficit hyperactivity]]></kwd>
<kwd lng="en"><![CDATA[disorder]]></kwd>
<kwd lng="en"><![CDATA[Neuropsychological test]]></kwd>
<kwd lng="en"><![CDATA[Neurocutaneous syndrome]]></kwd>
<kwd lng="en"><![CDATA[Paediatrics]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diggs-Andrews]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Gutmann]]></surname>
<given-names><![CDATA[DH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modeling cognitive dysfunction in neurofibromatosis-1]]></article-title>
<source><![CDATA[Trends Neurosci]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>237</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cutter]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cole-Plourde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Korf]]></surname>
<given-names><![CDATA[BR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurofibromatosis Clinical Trial Consortium]]></article-title>
<source><![CDATA[J Child Neurol]]></source>
<year>2018</year>
<volume>33</volume>
<page-range>82-91</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Giblin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Clancy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Huson]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service]]></article-title>
<source><![CDATA[Am J Med Genet]]></source>
<year>2010</year>
<volume>152</volume>
<page-range>327-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lehtonen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Trump]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognition in children with neurofibromatosis type 1: Data from a population-based study]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2015</year>
<volume>57</volume>
<page-range>645-51</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyman]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Shores]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[North]]></surname>
<given-names><![CDATA[KN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Learning disabilities in children with neurofibromatosis type 1: Subtypes, cognitive profile, and attention-deficit-hyperactivity disorder]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2006</year>
<volume>48</volume>
<page-range>973-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaucheret Paz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[López Ballent]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puga]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García Basalo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baliarda]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ekonen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive profile and disorders affecting higher brain functions in paediatric patients with neurofibromatosis type 1]]></article-title>
<source><![CDATA[Neurologia]]></source>
<year>2019</year>
<volume>34</volume>
<page-range>353-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Kaczorowski]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[MT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains]]></article-title>
<source><![CDATA[Child's Nerv Syst]]></source>
<year>2020</year>
<volume>36</volume>
<page-range>2321-32</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morotti]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mastel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Barnard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[O'Roak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2021</year>
<volume>63</volume>
<page-range>226-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beaussart-Corbat]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Barbarot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Farges]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Executive functions in preschool-aged children with neurofibromatosis type 1: Value for early assessment]]></article-title>
<source><![CDATA[J Clin Exp Neuropsychol]]></source>
<year>2021</year>
<volume>43</volume>
<page-range>163-75</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hyman]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Shores]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[North]]></surname>
<given-names><![CDATA[KN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior]]></article-title>
<source><![CDATA[Child Neuropsychol]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>313-29</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lidzba]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Granström]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lindenau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mautner]]></surname>
<given-names><![CDATA[VF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2012</year>
<volume>54</volume>
<page-range>892-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roulin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gras-Le Guen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Corbat]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Barbarot]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Executive functions and quality of life in children with neurofibromatosis type 1]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2021</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Pride]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Haebich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social skills and autism spectrum disorder symptoms in children with neurofibromatosis type 1: evidence for clinical trial outcomes]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2020</year>
<volume>62</volume>
<page-range>813-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pride]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchins]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coghill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Korgaonkar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hearps]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: A study protocol for a randomised placebo-controlled crossover trial]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2018</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pride]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Korgaonkar]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[North]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study]]></article-title>
<source><![CDATA[Cortex]]></source>
<year>2017</year>
<volume>93</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diggs-Andrews]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Tokuda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Izumi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zorumski]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Wozniak]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Gutmann]]></surname>
<given-names><![CDATA[DH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>309-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Na]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[TG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Wechsler Intelligence Scale for Children-V: Test Review]]></article-title>
<source><![CDATA[Appl Neuropsychol Child]]></source>
<year>2016</year>
<volume>5</volume>
<page-range>156-60</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kreutzer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[DelLuca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Caplan]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Encyclopedia of Clinical Neuropsychology]]></source>
<year>2018</year>
<publisher-name><![CDATA[Springer International]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nupan]]></surname>
<given-names><![CDATA[MMT]]></given-names>
</name>
<name>
<surname><![CDATA[Van Meerbeke]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Cabra]]></surname>
<given-names><![CDATA[CAL]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[PMH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive and behavioral disorders in children with neurofibromatosis type 1]]></article-title>
<source><![CDATA[Front Pediatr]]></source>
<year>2017</year>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heimgártner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Granström]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haas-Lude]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Leark]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Mautner]]></surname>
<given-names><![CDATA[V-F]]></given-names>
</name>
<name>
<surname><![CDATA[Lidzba]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attention deficit predicts intellectual functioning in children with neurofibromatosis type 1]]></article-title>
<source><![CDATA[Int J Pediatr]]></source>
<year>2019</year>
<volume>2019</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Potvin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[KS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relation between ADHD and cognitive profiles of children with NF1]]></article-title>
<source><![CDATA[J Pediatr Neuropsychol]]></source>
<year>2015</year>
<volume>1</volume>
<page-range>42-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Haebich]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[MacKenzie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Hearps]]></surname>
<given-names><![CDATA[SJC]]></given-names>
</name>
<name>
<surname><![CDATA[Coghill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1]]></article-title>
<source><![CDATA[J Atten Disord]]></source>
<year>2021</year>
<volume>25</volume>
<page-range>1177-86</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mautner]]></surname>
<given-names><![CDATA[V-F]]></given-names>
</name>
<name>
<surname><![CDATA[Kluwe]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Thakker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Leark]]></surname>
<given-names><![CDATA[RA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of ADHD in neurofibromatosis type 1]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2002</year>
<volume>44</volume>
<page-range>164</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lion-Francois]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Herbillon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Peyric]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mercier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gérard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ginhoux]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF1 + ADHD) and ADHD Per Se]]></article-title>
<source><![CDATA[J Atten Disord]]></source>
<year>2020</year>
<volume>24</volume>
<page-range>1807-23</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Halevy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aharon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shuper]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attention deficit hyperactivity disorder in neurofibromatosis type 1: Evaluation with a continuous performance test]]></article-title>
<source><![CDATA[J Clin Neurol]]></source>
<year>2018</year>
<volume>14</volume>
<page-range>153-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michael]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Herbillon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lion-Francois]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reactivity to visual signals in neurofibromatosis type 1: Is everything ok?]]></article-title>
<source><![CDATA[Neuropsychology]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>423-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galasso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lo-Castro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carlo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pitzianti]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[D'Agati]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Curatolo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Planning deficit in children with neurofibromatosis type 1: A neurocognitive trait independent from attention-deficit hyperactivity disorder (ADHD)?]]></article-title>
<source><![CDATA[J Child Neurol]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>1320-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
